"Colossal is thrilled to welcome Viagen, the world’s leading cloning company, into our portfolio. No other company comes close to what Viagen has achieved," Colossal founder and CEO Ben Lamm said of the merger. "Their unmatched expertise and cloning technology stack have become the world’s standard, and their application of these critical and proprietary technologies to endangered species conservation makes them an invaluable partner in advancing our global de-extinction and species preservation mission."
"Colossal’s acquisition of Viagen is just another exciting step in their path to bringing back earth’s biodiversity in volume," she said in a press release following the acquisition.
In recent years, Colossal has been inching towards bringing back the woolly mammoth, the dodo, and the Tasmanian tiger from extinction. After successfully achieving de-extinction with the birth of two male dire wolves in October 2024, followed by a female in January, Colossal is creating a genetic vault of dozens of threatened species, including the "critically endangered black rhino and threatened white rhino.
"Viagen’s proprietary technology will fuel Colossal’s de-extinction efforts," Colossal’s Chief Animal Officer Matt James explained.
Hence then, the article about company behind tom brady s cloned dog acquired by bioscience company that resurrected dire wolves was published today ( ) and is available on Parade ( Saudi Arabia ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Company Behind Tom Brady's Cloned Dog Acquired by Bioscience Company That Resurrected Dire Wolves )
Also on site :